title: Part 1: Vesicoureteral reflux treatment: the past, present, and future.
abstract: The purpose of this manuscript is to provide clinicians with highlights of key findings pertaining to our current understanding and treatment of the condition of vesicoureteral reflux (VUR). This includes a review of the disease, patient characteristics, current treatment options, challenges for managed care and patients, and opportunities for improvements in care. This is not intended as a comprehensive review of VUR. This manuscript does, however, serve to introduce three additional manuscripts contained within this supplement. The first article in this series is designed to provide the clinician with real-world data pertaining to treatment patterns and outcomes in patients with VUR (Examining pediatric vesicoureteral reflux: a real-world evaluation of treatment patterns and outcomes: Hensle TW, Hyun G, Grogg AL, Eaddy M). The second article considers the efficacy of prophylactic antibiotics in reducing the likelihood of urinary tract infections (UTIs) when compared with endoscopic injection with dextranomer/hyaluronic acid (Endoscopic injection versus antibiotic prophylaxis in the reduction of urinary tract infection in patients with vesicoureteral reflux: Elder JS, Shah MB, Batiste LR, et al.). The third article explores the role medication noncompliance plays in contributing to antibiotic resistance, the consequences associated with resistance (longer lasting illness and costs), and the difficulties with resistance specific to UTI pathogens in children (Considerations regarding the medical management of VUR: what have we really learned?: Koyle MA, Caldamone A). This supplement is intended to provide the clinician with valuable information regarding the treatment patterns, the role of compliance, and the efficacy of treatments for pediatric patients with VUR.
authors.affiliation: Columbia University, College of Physicians and Surgeons, New York, NY, USA.
authors.forename: Terry W
authors.initials: TW
authors.lastname: Hensle
authors.forename: Amy L
authors.initials: AL
authors.lastname: Grogg
mesh_terms: D000328:Adult; D001741:Black or African American; D000367:Age Factors; D001437:Bacteriuria / Q000175:diagnosis / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D002921:Cicatrix / Q000175:diagnosis / Q000209:etiology / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000628:therapy; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008297:Male; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000628:therapy; D011704:Pyelonephritis / Q000175:diagnosis / Q000209:etiology / Q000235:genetics / Q000382:microbiology / Q000401:mortality / Q000473:pathology; D012737:Sex Factors; D001743:Urinary Bladder / Q000382:microbiology / Q000473:pathology; D014718:Vesico-Ureteral Reflux / Q000150:complications / Q000175:diagnosis / Q000382:microbiology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D044465:White People